MPL W515L is uncommon in myeloproliferative diseases but is associated with abnormal STAT5 activation similar to that seen with JAK2 V617F

被引：0
|
作者：
Schade, A. E. [1 ]
Szpurka, H. [1 ]
Bak, B. [1 ]
Maciejewski, J. P. [1 ]
Hsi, E. D. [1 ]
机构：
[1] Cleveland Clin, Cleveland, OH 44106 USA
来源：
MODERN PATHOLOGY | 2007年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R36 [病理学];
学科分类号：
100104 ;
摘要：
1188
引用
收藏
页码：259A / 259A
页数：1
相关论文
共 50 条
  • [41] Effects of a novel, selective Jak2 inhibitor, AZ60, on STAT5 signaling and cellular growth in Jak2 V617F cell lines
    Gozgit, Joseph M.
    Bebernitz, Geraldine A.
    Patil, Pankaj
    Ye, Minwei
    Wu, Jiaquan
    Ioannidis, Stephanos
    Davies, Audrey
    Wang, Tao
    Huszar, Dennis
    Zinda, Michael
    BLOOD, 2007, 110 (11) : 1039A - 1039A
  • [42] THROMBOEMBOLIC AND HEMORRHAGIC COMPLICATIONS AND JAK2 V617F MUTATION POSITIVITY IN PHILADELPHIA NEGATIVE MYELOPROLIFERATIVE DISEASES
    Unubol, M.
    Yavsoglu, I.
    Bozkurt, G.
    Kadikoylu, G.
    Bolaman, Z.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 590 - 590
  • [43] Validity test study of JAK2 V617F and allele burden quantification in the diagnosis of myeloproliferative diseases
    Rapado, Inmaculada
    Albizua, Enriqueta
    Ayala, Rosa
    Angel Hernandez, Jose
    Garcia-Alonso, Luis
    Grande, Silvia
    Gallardo, Miguel
    Gilsanz, Florinda
    Martinez-Lopez, Joaquin
    ANNALS OF HEMATOLOGY, 2008, 87 (09) : 741 - 749
  • [44] Ectopic PD-L1 expression in JAK2 (V617F) myeloproliferative neoplasm patients is mediated via increased activation of STAT3 and STAT5 (vol 43, pg 631, 2020)
    Guru, Sameer Ahamd
    Sumi, Mamta P.
    Mir, Rashid
    Waza, Ajaz Ahmad
    Bhat, Musadiq Ahmad
    Zuberi, Mariyam
    Lali, Promod
    Saxena, Alpana
    HUMAN CELL, 2020, 33 (04) : 1334 - 1334
  • [45] Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2
    Kralovics, R
    Teo, SS
    Buser, AS
    Brutsche, M
    Tiedt, R
    Tichelli, A
    Passamonti, F
    Pietra, D
    Cazzola, M
    Skoda, RC
    BLOOD, 2005, 106 (10) : 3374 - 3376
  • [46] Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype
    Cross, Nicholas C. P.
    Jones, Amy V.
    Silver, Richard T.
    Oscier, David
    Metzgeroth, Georgia
    Wang, Y. Lynn
    Collins, Andrew
    Reiter, Andreas
    Grand, Francis
    Chase, Andrew
    BLOOD, 2008, 112 (11) : 71 - 71
  • [47] MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling
    Francesca Pagano
    Federico Comoglio
    Jacob Grinfeld
    Juan Li
    Anna Godfrey
    Joanna Baxter
    Yvonne Silber
    Anthony R Green
    Leukemia, 2018, 32 : 1826 - 1830
  • [48] Oncogenic signaling pathway induced by myeloproliferative neoplasm-associated JAK2 V617F mutant
    Funakoshi-Tago, M.
    FEBS JOURNAL, 2012, 279 : 3 - 3
  • [49] MicroRNA-101 expression is associated with JAK2V617F activity and regulates JAK2/STAT5 signaling
    Pagano, Francesca
    Comoglio, Federico
    Grinfeld, Jacob
    Li, Juan
    Godfrey, Anna
    Baxter, Joanna
    Silber, Yvonne
    Green, Anthony R.
    LEUKEMIA, 2018, 32 (08) : 1826 - 1830
  • [50] Thrombopoietin Receptor (MPL) Genotype Modifies the Myeloproliferative Phenotype in a JAK2 V617F Transgenic Mouse Model of Polycythemia Vera
    Spivak, Vera. Jerry L.
    Williams, Donna M.
    Stein, Brady L.
    Rogers, Ophelia
    Hochman, Tsivia
    Goldberg, Judith D.
    Zhao, Wanming
    Zhao, Zhizhuang Joe
    Moliterno, Alison R.
    BLOOD, 2009, 114 (22) : 398 - 399
12345